XML 95 R83.htm IDEA: XBRL DOCUMENT
v3.25.3

Commitments and Contingencies (Details) $ in Thousands |  |  |  |  | 1 Months Ended | 2 Months Ended | 18 Months Ended
--- | --- | --- | --- | --- | --- | --- | ---
Mar. 08, 2023 USD ($) | Feb. 28, 2022 case | Sep. 11, 2020 | Mar. 24, 2015 patent | Jun. 30, 2025 USD ($) | May 31, 2025 USD ($) | Mar. 31, 2022 stockholder case | Mar. 31, 2022 stockholder | Apr. 30, 2017 patent lawsuit
Xtampza ER Litigation |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |
Stay period before FDA can issue a final approval unless it is terminated |  |  |  | 30 months |  |  |  |  |
Number of patents allegedly infringed | patent |  |  |  | 3 |  |  |  |  | 2
Number of lawsuits filed | lawsuit |  |  |  |  |  |  |  |  | 2
Statutory period of proceedings |  |  | 18 months |  |  |  |  |  |
Xtampza ER Litigation, District of Massachusetts |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |
Stay period before FDA can issue a final approval unless it is terminated |  |  |  | 30 months |  |  |  |  |
Number of patents allegedly infringed | patent |  |  |  | 3 |  |  |  |  |
BDSI Acquisition Litigation |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |
Number of additional cases filed | case |  | 2 |  |  |  |  | 2 |  |
Number of demand letters received from purported stockholders | stockholder |  |  |  |  |  |  | 4 | 3 |
Aquestive Therapeutics, Inc Litigation | Selling, General and Administrative Expenses [Member] |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |
Litigation settlement, amount awarded to other party | $ 8,500 |  |  |  |  |  |  |  |
Arbitration request from North Sound Pharmaceuticals, Inc. | Minimum |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |
Compensatory damages |  |  |  |  |  | $ 500,000 |  |  |
Lawsuit filed by Walgreen Co | Minimum |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |
Compensatory damages |  |  |  |  | $ 14,000 |  |  |  |

X
- Definition Number of additional cases filed. + References No definition available. + Details
Name: | coll_LossContingencyNumberOfAdditionalCasesFiled
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of demand letters received from purported stockholders. + References No definition available. + Details
Name: | coll_LossContingencyNumberOfDemandLettersReceivedFromPurportedStockholders
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the stay period before the Federal Drug Administration (FDA) can issue final approval unless the stay is terminated. + References No definition available. + Details
Name: | coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected
Namespace Prefix: | coll_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Statutory period of proceedings. + References No definition available. + Details
Name: | coll_StatutoryPeriodOfProceedings
Namespace Prefix: | coll_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LitigationSettlementLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The value (monetary amount) of the award the plaintiff seeks in the legal matter. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The total number of new claims filed pertaining to a loss contingency during the period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity has allegedly infringed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_BdsiAcquisitionLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_AquestiveTherapeuticsIncLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_ArbitrationWithNorthSoundPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_WalgreenCo.LawsuitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |